Research has shown that the loss of BACH1 enhances the anti‐tumor effect on mantle cell lymphoma cells by stimulating intrinsic antitumor immune responses and inhibiting cell cycle arrest.[309] Another study suggests a thermosensitive gel‐nano system for EC treatment through small interfering RNA targeting BACH1 and p53 activator PRIMA‐1, restoring anti‐tumor immune responses, has potential for clinical application.[310] Further research is needed on the regulatory mechanism of BACH1 in the TME as an anti‐tumor therapy. Here, TP53 is linked to neoplasm.